{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:16:44Z","timestamp":1788419804475,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to investigate the association between serum soluble ST2 (sST2) and liver injury biomarkers in patients with acute heart failure (AHF), and to evaluate the potential value of sST2 in identifying liver injury in AHF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 134 patients with AHF (with or without liver injury) were prospectively enrolled, along with 187 age- and sex-matched healthy controls. Serum sST2 were measured within 24\u2005h of hospital admission, along with comprehensive clinical and laboratory assessments. Univariate and multivariate linear regression analyses were performed to explore the relationships between sST2 and liver function parameters. ROC curve analysis was used to evaluate the discriminative ability of sST2 for liver injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Univariate analysis showed that sST2 had weak but statistically significant correlations with NT-proBNP (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.20), TBIL (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.26), and GGT (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.19), moderately weak correlations with DBIL (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.32) and ALP (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.35), and strong correlations with AST (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.71) and ALT (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.55) (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). No significant association was observed between sST2 and cTnI (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.07,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.485). In multivariate regression, NT-proBNP (\u03b2\u2009=\u20090.001,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.009), AST (\u03b2\u2009=\u20090.230,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), and DBIL (\u03b2\u2009=\u20091.028,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003) were identified as independent predictors of sST2. Patients with liver injury had significantly higher sST2 levels (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002). ROC analysis demonstrated that sST2 predicted liver injury with an AUC of 0.691, which was superior to NT-proBNP (AUC\u2009=\u20090.545). The combined model of sST2, AST, and DBIL yielded an AUC of 0.905, with a sensitivity of 85.2% and a specificity of 85.0%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum sST2 is strongly associated with liver injury markers, particularly AST and DBIL, in patients with AHF. Elevated sST2 is associated with underlying hepatic dysfunction and may serve as a potential biomarker linking cardiac decompensation and liver impairment. Although sST2 alone has limited sensitivity for liver injury, a combined panel of sST2, AST, and DBIL provides excellent diagnostic performance. This combined approach may serve as a useful tool for risk stratification and early identification of cardiogenic liver injury.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1781835","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:44:40Z","timestamp":1788417880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of sST2 with liver function in patients with acute heart failure related hospitalization"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhenyi","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, BaiShan Central Hospital","place":["Baishan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European Society of Cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure: endorsed by the Canadian heart failure society, heart failure association of India, cardiac society of Australia and New Zealand, and Chinese heart failure association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchf.2018.10.007","article-title":"Heart failure and liver disease: cardiohepatic interactions","volume":"7","author":"Xanthopoulos","year":"2019","journal-title":"JACC Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2017.10.016","article-title":"Liver disease and heart failure: back and forth","volume":"48","author":"Correale","year":"2018","journal-title":"Eur J Intern Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e030823219400","DOI":"10.2174\/1874467217666230803114856","article-title":"Hepatic ischemia-reperfusion injury: protective approaches and treatment","volume":"17","author":"Singh","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clinre.2014.10.012","article-title":"Overexpression of Serum Sst2 is associated with poor prognosis in acute-on-chronic hepatitis B liver failure","volume":"39","author":"Gao","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12876-023-03116-4","article-title":"Evaluation of soluble suppression of tumorigenicity 2 (Sst2) as Serum marker for liver fibrosis","volume":"24","author":"Hildenbrand","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/jcmm.13990","article-title":"Plasma levels of soluble St2, but not il-33, correlate with the severity of alcoholic liver disease","volume":"23","author":"Sun","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3390\/jcm12123970","article-title":"Prognostic value of Sst2 in heart failure","volume":"12","author":"Sciatti","year":"2023","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 Aha\/acc\/hfsa guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/jcm8020270","article-title":"Cardiac biomarkers in the emergency department: the role of soluble St2 (Sst2) in acute heart failure and acute coronary syndrome-there is meat on the bone","volume":"8","author":"Aleksova","year":"2019","journal-title":"J Clin Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The il-33\/St2 pathway: therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1533335","DOI":"10.3389\/fimmu.2025.1533335","article-title":"Il-33\/St2 axis in diverse diseases: regulatory mechanisms and therapeutic potential","volume":"16","author":"Sheng","year":"2025","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.26599\/1671-5411.2025.03.002","article-title":"Chinese Guidelines for the diagnosis and treatment of heart failure 2024","volume":"22","author":"Zhang","year":"2025","journal-title":"J Geriatr Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3969\/j.issn.1002-1949.2024.01.002","article-title":"Expert consensus on diagnosis and treatment of acute liver injury in the emergency setting","volume":"44","year":"2024","journal-title":"Chinese J Crit Care Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cardfail.2009.08.002","article-title":"Abnormal liver function in relation to hemodynamic profile in heart failure patients","volume":"16","author":"Van Deursen","year":"2010","journal-title":"J Card Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.jacc.2013.03.042","article-title":"Cardiohepatic interactions in heart failure: an overview and clinical implications","volume":"61","author":"Samsky","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/eurjhf\/hfn031","article-title":"Liver function abnormalities and outcome in patients with chronic heart failure: data from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program","volume":"11","author":"Allen","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2362.2011.02573.x","article-title":"Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance","volume":"42","author":"Poelzl","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3B","DOI":"10.1016\/j.amjcard.2015.01.034","article-title":"The biology of St2: the international St2 consensus panel","volume":"115","author":"Pascual-Figal","year":"2015","journal-title":"Am J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"eabl7209","DOI":"10.1126\/sciimmunol.abl7209","article-title":"Gasdermin D-mediated release of il-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma","volume":"7","author":"Yamagishi","year":"2022","journal-title":"Sci Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e005488","DOI":"10.1161\/CIRCHEARTFAILURE.118.005488","article-title":"Pulmonary production of soluble St2 in heart failure","volume":"11","author":"Pascual-Figal","year":"2018","journal-title":"Circ Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"618816","DOI":"10.3389\/fcvm.2021.618816","article-title":"Prognostic implication of liver function tests in heart failure with preserved ejection fraction without chronic hepatic diseases: insight from topcat trial","volume":"8","author":"Liang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13104-020-05031-3","article-title":"Ast\/alt ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction","volume":"13","author":"Ewid","year":"2020","journal-title":"BMC Res Notes"},{"key":"B26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/ejhf.872","article-title":"Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the acute heart failure committee of the heart failure association (hfa) of the European Society of Cardiology (esc)","volume":"19","author":"Harjola","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/01.md.0000101573.54295.bd","article-title":"Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases","volume":"82","author":"Henrion","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.14218\/JCTH.2016.00022","article-title":"Hypoxic hepatitis: a review and clinical update","volume":"4","author":"Waseem","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/cmi.2016.63","article-title":"Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells","volume":"15","author":"Tan","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cca.2020.04.011","article-title":"Soluble St2: a Complex and diverse role in several diseases","volume":"507","author":"Homsak","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"Il-33 and St2 comprise a critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/ehjacc\/zuae036.070","article-title":"Diagnostic and prognostic value of nt-probnp in patients with non-alcoholic fatty liver disease and acute decompensated heart failure","volume":"13","author":"Khutsishvili","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1781835\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:44:41Z","timestamp":1788417881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1781835\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":32,"alternative-id":["10.3389\/fcvm.2026.1781835"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1781835","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1781835"}}